METHODS & RESULTS: P. acidilactici R037 was orally administered to EAE mice to investigate the effects of R037. R037 treatment suppressed clinical EAE severity as prophylaxis and therapy.
CONCLUSIONS: An orally administered single strain of P. acidilactici R037 ameliorates EAE by inducing regulatory cells. Their findings indicate the therapeutic potential of the oral administration of R037 for treating MS.
"Interesting study; I wonder if the same effects will be seen in humans. Can you imagine the nutriceutical industry getting involved with this? Danone or Nestle sponsor lactobacillus trial in MS!!"